Chapter 51 Fibromyalgia

Handbook of Clinical Neurology

Volumn 81, Issue , 2006, Pages 763-777

  Kosek, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649369570     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(06)80055-2     Document Type: Article

References (145)

1. Aaron L., Bradley L.A., Alarcón G.S., Triana-Alexander M., Alexander R.W., Martin M.Y., and Alberts K.R. Perceived physical and emotional trauma as precipitating events in fibromyalgia. Arthr Rheum 40 (1997) 453-460
2. Anderberg U.M., Liu Z., Berglund L., and Nyberg F. Elevated plasma levels of neuropeptide Y in female fibromyalgia syndrome patients. Eur J Pain 3 (1999) 19-30
3. Arnold L.M., Keck P.E., and Welge J.A. Anti-depressant treatment of fibromyalgia. Psychosomatics 41 (2000) 104-113
4. Arnold L., Lu Y., Crofford L., Wohlreich M., Detke M., Iyengar S., Goldstein D., and Duloxetine Fibromyalgia Trial Group. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressivedisorder. Arthritis Rheum 50 (2004) 2974-2984
5. Bendtsen L., Jensen R., and Olesen J. Qualitatively altered nociception in chronic myofascial pain. Pain 65 (1996) 259-264
6. Bengtsson A., Henriksson K.-G., and Larsson J. Muscle biopsy in primary fibromyalgia. Light microscopical and histochemical findings. Scand J Rheumatol 15 (1986) 1-6
7. Bengtsson A., Henriksson K.G., and Larsson J. Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 29 (1986) 817-821
8. Bengtsson A., Bäckman E., Lindblom B., and Skogh T. Long term follow-up of fibromyalgia patients: Clinical symptoms, muscular function, laboratory tests - an eight year comparison study. J Musculoskel Pain 2 (1994) 67-80
9. Bengtsson M., Bengtsson A., and Jorfeldt L. Diagnostic epidural opioid blockade in primary fibromyalgia at rest and during exercise. Pain 39 (1989) 171-180
10. Bennett R.M. Physical fitness and muscle metabolism in the fibromyalgia syndrome: An overview. J Rheumatol 16 Suppl. 19 (1989) 28-29
11. Bennett R.M. Emerging concepts in the neurobiology of chronic pain: Evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 74 (1999) 385-398
12. Bennett R.M., Cook D.M., Clark S.R., Burckhardt C.S., and Campbell S.M. Hypothalamic-pituitary- insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 24 (1997) 1384-1389
13. Bennett R.M., Clark S.C., and Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104 (1998) 227-231
14. Bennett R.M., Kamin M., Karim R., and Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114 (2003) 537-545
15. Berglund B., Harju E.-L., and Lindblom U. Psychophysical testing of somatosensory functions in neuropathic-pain patients. In: Jensen T., Turner J., and Wiesenfeld-Hallin Z. (Eds). Progress in Pain Research and Management. Proceedings of the 8th World Congress on Pain (1997), IASP Press, Seattle 435-447
16. Berglund B., Harju E.-L., Kosek E., and Lindblom U. Quantitative and qualitative perceptual analysis of cold dysesthesia and hyperalgesia in fibromyalgia. Pain 96 (2002) 177-187
17. Bergman S., Herrström P., Högström K., Petersson I.F., Svensson B., and Jacobsson L. Chronic musculoskeletal pain, prevalence rates, and sociodemographic associations in a Swedish population study. J Rheumatol 28 (2001) 1369-1377
18. Bergman S., Herrström P., Jacobsson L., and Petersson I. Chronic widespread pain: a three year followup of pain distribution and risk factors. J Rheumatol 29 (2002) 818-825
19. Biasi G., Manca S., Manganelli S., and Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 18 (1998) 13-19
20. Bradley L.A., McKendree-Smith N.L., Alberts K.R., Alarcón G.S., Mountz J.M., and Deutsch G. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep 2 (2000) 141-148
21. Brattberg G. Connective tissue massage in the treatment of fibromyalgia. Eur J Pain 3 (1999) 235-245
22. Buskila D., Neumann L., Vaisberg G., Alkalay D., and Wolfe F. Increased rates of fibromyalgia following cervical spine injury. Arthritis Rheum 40 (1997) 446-452
23. Carette S., Oakson G., Guimont C., and Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 38 (1995) 1211-1217
24. Carmona L., Ballina J., Gabriel R., and Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60 (2001) 1040-1045
25. Clarke S., Tindall E., and Bennett R.M. A double-blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 12 (1985) 980-983
26. Clauw D., Schmidt M., Radulovic D., Singer A., Katz P., and Bresette J. The relationship between fibromyalgia and interstitial cystitis. J Psychiatr Res 31 (1997) 125-131
27. Cohen H., Neumann L., Kotler M., and Buskila D. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. IMAJ 3 (2001) 755-760
28. Crofford L.J. Neuroendocrine abnormalities in fibromyalgia and related disorders. Am J Med Sci 315 (1998) 359-366
29. Crofford L.J., Rowbotham M., Mease P., Russell J., Dworkin R., Corbin A., Young J., LaMoreaux L., Martin S., Sharma U., and Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome. Results of a randomized, double-blind, placebo-controlled trial. Arthritis & Rheum 52 (2005) 1264-1273
30. Croft P., Schollum J., and Silman A. Population study of tender points counts and pain as evidence of fibromyalgia. BMJ 309 (1994) 696-699
31. Davis M., Zautra A., and Reich J. Vulnerability to stress among women in chronic pain from fibromyalgia and osteoarthritis. Ann Behav Med 23 (2001) 215-226
32. Desmeules J., Cedraschi C., Rapiti E., Baumgartner E., Finckh A., Cohen P., Dayer P., and Vischer T. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 48 (2003) 1420-1429
33. Elvín A., Siosteen A., Nilsson A., and Kosek E. Decreased muscle blood flow in fibromyalgia patients during standardized muscle exercise. A contrast media enhanced colour doppler study. Eur J Pain 10 (2005) 137-144
34. Epstein S., Kay G., Clauw D., Heaton R., Klein D., Krupp L., Kuck J., Leslie V., Masur D., Wagner M., Waid R., and Zisook S. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 40 (1999) 57-63
35. Evengard B., Nilsson C.G., Lindh G., Lindquist L., Eneroth P., Fredriksson S., Terenius L., and Henriksson K.G. Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronicfatigue syndrome. Pain 78 (1998) 153-155
36. Fassbender K., Samborsky W., Kellner M., Muller W., and Lautenbacher S. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clin Rheumatol 16 (1997) 76-79
37. Forseth K., Gran J., and Husby G. Incidence of fibromyalgia among females aged 26-55 years. Br J Rheumatol 36 (1997) 1318-1323
38. Forseth K.O., Forre O., and Gran J.T. A 5.5 year prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population: Significance and natural history. Clin Rheumatol 18 (1999) 114-121
39. Forseth K.O., Husby G., Gran J.T., and Forre O. Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. J Rheumatol 26 (1999) 2458-2467
40. 2 laser stimulation in subjects with fibromyalgia syndrome. Pain 58 (1994) 185-193
41. Giovengo S., Russell I., and Larson A. Increased concentration of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 26 (1999) 1564-1569
42. Gracely R., Petzke F., Wolf J., and Clauw D. Functional magnetic imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 6 (2002) 1333-1343
43. Granges G., and Littlejohn G. Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum 36 (1993) 642-646
44. Granges G., Zilko P., and Littlejohn G.O. Fibromyalgia syndrome: Assessment of the severity of the condition 2 years after diagnosis. J Rheumatol 21 (1994) 523-529
45. Graven-Nielsen T., Aspengren Kendall S., Henriksson K.G., Bengtsson M., Sorensen J., Johnson A., Gerdle B., and Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgia patients. Pain 85 (2000) 483-491
46. Griep E.N., Boersma J.W., and DeKloet E.R. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 20 (1993) 469-474
47. Griep E.N., Boersma J.W., Lentjes E.G., Prins A.P., van der Korst J.K., and de Kloet E.R. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 25 (1998) 1374-1381
48. Gustafsson M., Ekholm J., and Broman L. Effects of a multiprofessional rehabilitation programme for patients with fibromyalgia syndrome. J Rehabil Med 34 (2002) 1-9
49. Hakkinen A., Hakkinen K., Hannonen P., and Alen M. Strength training induced adaptations in neuromuscular function of premenopausal women with fibromyalgia: comparison with healthy women. Ann Rheum Dis 60 (2001) 21-26
50. Handler N., and Ehrlich G. Fibromyalgia and the conundrum of disability determination. JOEM 45 (2003) 1030-1033
51. Henriksson C. Living with continuous muscular pain - Patient perspectives. Part I: Encounters and consequences. Scand J Caring Sci 9 (1995) 67-76
52. Henriksson C., and Burckhardt C. Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. Disabil Rehabil 18 (1996) 241-248
53. Henriksson C., Carlberg U., Kjällman M., Lundberg G., and Henriksson K. Evaluation of four outpatient educational programmes for patients with longstanding fibromyalgia. J Rehabil Med 36 (2004) 211-219
54. Henriksson K.G. Is fibromyalgia a distinct clinical entity? Pain mechanisms in fibromyalgia syndrome. A myologist's view. Baillière's Clin Rheum 13 (1999) 455-461
55. Henriksson K.G., and Mense S. Pain and nociception in fibromyalgia: clinical and neurobiological considerations on aetiology and pathogenesis. Pain Rev 1 (1994) 245-260
56. Hughes G., Wessely S., Myon E., Taieb C., and Martinez C. Fibromyalgia syndrome (FMS) and healthcare resource use in the United Kingdom: Analysis of data in the general practice research database (GPRD). Ann Rheum Dis 63 Suppl. 1 (2004) 524
57. Jacobsen S., and Danneskiold-Samsoe B. Dynamic muscular endurance in primary fibromyalgia compared with chronic myofascial pain syndrome. Arch Phys Med Rehabil 73 (1992) 170-173
58. Jacobsen S., Wildschiodtz G., and Danneskiold-Samsoe B. Isokinetic and isometric muscle strength combined with transcutaneous electrical muscle stimulation in primary fibromyalgia syndrome. J Rheumatol 18 (1991) 1390-1393
59. Jacobsen S., Petersen I.S., and Danneskiold-Samsoe B. Clinical features in patients with chronic muscle pain - with special reference to fibromyalgia. Scand J Rheumatol 22 (1993) 69-76
60. Keefe F.J., Kashikar-Zuck S., Opiteck J., Hage E., Dalrymple I., and Blumenthal J.A. Pain in arthritis and musculoskeletal disorders: The role of coping skills training and exercise interventions. JOSPT 24 (1996) 279-289
61. Kosek E., and Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patientsand healthy subjects. Pain 70 (1997) 41-51
62. Kosek E., and Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur J Pain 4 (2000) 229-238
63. Kosek E., and Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following,surgical pain relief. Pain 88 (2000) 69-78
64. Kosek E., Ekholm J., and Hansson P. Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain 63 (1995) 335-339
65. Kosek E., Ekholm J., and Hansson P. Modulation of pressure pain thresholds during and following isometric contraction in patients with fibromyalgia and in healthy controls. Pain 64 (1996) 415-423
66. Kosek E., Ekholm J., and Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 68 (1996) 375-383
67. Langemark M., Jensen K., Jensen T.S., and Olesen J. Pressure pain thresholds and thermal nociceptive thresholds in chronic tension-type headache. Pain 38 (1989) 203-210
68. Lápossy E., Maleitzke R., Hrycaj P., Mennet W., and Müller W. The frequency of transition of chronic low back pain to fibromyalgia. Scand J Rheumatol 24 (1995) 29-33
69. Larsson S., Bodegard L., Henriksson K., and Oberg P. Chronic trapezius myalgia. Morphology and blood flow studied in 17 patients. Acta Orthop Scand 61 (1990) 394-398
70. Larsson R., Öberg ., and Larsson S.E. Changes of trapezius muscle blood flow and electromyography in chronic neck pain due to trapezius myalgia. Pain 79 (1999) 45-50
71. Lautenbacher S., and Rollman G.B. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 13 (1997) 189-196
72. Lautenbacher S., Rollman G.B., and McCain G.A. Multimethod assessment of experimental and clinical pain in patients with fibromyalgia. Pain 59 (1994) 45-53
73. Lautenschläger J., Seglias J., Brückle W., and Müller W. Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia. Clin Rheumatol 10 (1991) 168-174
74. LeBars D., Dickenson A.H., and Besson J.M. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 6 (1979) 283-304
75. Leffler A.S., Kosek E., Lerndal T., Nordmark B., and Hansson P. Somatosensory perception and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from rheumatoid arthritis. Eur J Pain 6 (2002) 161-176
76. Leffler A.S., Hansson P., and Kosek E. Somatosensory perception in a remote pain-free area and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from long-termtrapezius myalgia. Eur J Pain 6 (2002) 149-159
77. Leffler A.S., Hansson P., and Kosek E. Somatosensory perception in patients suffering from long-term trapezius myalgia at the site overlying the most painful part of the muscle and in an area of pa. Eur J Pain 7 (2003) 267-276
78. Liedberg G.M., and Henriksson C. Factors of importance for work disability in women with fibromyalgia: an interview study. Arthritis Rheum 47 (2002) 266-274
79. Lindell L., Bergman S., Petersson I.F., Jacobsson L.T.H., and Herrström P. Prevalence of fibromyalgia and chronic widespread pain. Scand J Prim Health Care 18 (2000) 149-153
80. Lindh C., Liu Z., Lyrenäs S., Ordeberg G., and Nyberg F. Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopathic painfrom a herniated lumbar disc. Scand J Rheumatol 26 (1997) 468-472
81. Lindman R., Eriksson A., and Thornell L. Fiber type composition of the human female trapezius muscle: enzyme-histochemical characteristics. Am J Anat 190 (1991) 385-392
82. Lindman R., Hagberg M., Angqvist K., Söderlund K., Hultman E., and Thornell L. Changes in muscle morphology in chronic trapezius myalgia. Scand J Work Environ Health 17 (1991) 347-355
83. Lorenz J., Grasedyck K., and Bromm B. Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. Electroencephalogr Clin Neurophysiol 100 (1996) 165-168
84. Lund N., Bengtsson A., and Thorborg P. Muscle oxygen pressure in primary fibromyalgia. Scand J Rheumatol 15 (1986) 165-173
85. Lund E., Kendall S.A., Janerot-Sjöberg B., and Bengtsson A. Muscle metabolism in fibromyalgia studied by P-31 magnetic resonance spectroscopy during aerobic and anaerobic exercise. Scand J Rheumatol 32 (2003) 138-145
86. MacFarlane G., Thomas E., Papageorgiou A., Schollum J., Croft P., and Silman A. The natural history of chronic pain in the community: a better prognosis than in the clinic?. J Rheumatol 23 (1996) 1617-1620
87. Madeleine P., Lundager B., Voigt M., and Arendt-Nielsen L. Sensory manifestations in experimental and work-related chronic neck-shoulder pain. Eur J Pain 2 (1998) 251-260
88. Maixner W., Fillingim R., Booker D., and Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain 63 (1995) 341-351
89. Mannerkorpi K., Ahlmen M., and Ekdahl C. Six- and 24-month follow-up of pool exercise therapy and education for patients with fibromyalgia. Scand J Rheumatol 31 (2002) 306-310
90. Marhold C., Linton S., and Melin L. A cognitive-behavioral return-to-work program: effects on pain patients with a history of long-term versus short-term sick leave. Pain 91 (2001) 155-163
91. Martinez-Lavin M., Vidal M., Barbosa R.E., Pineda C., Casanova J.M., and Nava A. Norepinephrine-evoked pain in fibromyalgia. A randomized pilot study. BMC Musculoskel Dis 3 (2002) 2
92. McBeth J., and Silman A.J. The role of psychiatric disorders in fibromyalgia. Curr Rheumatol Rep 3 (2001) 157-164
93. McCain G., Bell D., Mai F., and Halliday P. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 31 (1988) 1135-1141
94. Meiworm L., Jakob E., Walker U., Peter H., and Keul J. Patients with fibromyalgia benefit from aerobic endurance exercise. Clin Rheumatol 19 (2000) 253-257
95. Mengshoel A., Komnaes H., and Forre O. The effects of 20 weeks of physical fitness training in female patients with fibromyalgia. Clin Exp Rheumatol 10 (1992) 345-349
96. Mengshoel A.M., Saugen E., Forre O., and Vollestad N.K. Muscle fatigue in early fibromyalgia. J Rheumatol 22 (1995) 143-150
97. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain 54 (1993) 241-289
98. Mikkelsson M., Latikka P., Kautiainen H., Isomeri R., and Isomäki H. Muscle and bone pressure pain threshold and pain tolerance in fibromyalgia patients and controls. Arch Phys Med Rehabil 73 (1992) 814-818
99. Moldofsky H. Management of sleep disorders in fibromyalgia. Rheum Dis Clin N Am 28 (2002) 353-365
100. Neumann L., and Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 7 (2003) 362-368
101. Nimnuan C., Rabe-Hesketh S., Wessely S., and Hotopf M. How many functional somatic syndromes?. J Psychosom Res 51 (2001) 549-557
102. O'Driscoll S.L., and Jayson M.I. Pain threshold analysis in patients with osteoarthritis of hip. Br Med J 3 (1974) 714-715
103. Offenbacher M., and Stucki G. Physical therapy in the treatment of fibromyalgia. Scand J Rheumatol 113 (2000) 78-85
104. Ohrbach R., and Gale E.N. Pressure pain thresholds, clinical assessment, and differential diagnosis: reliability and validity in patients with myogenic pain. Pain 39 (1989) 157-169
105. Okifuji A., Turk D.C., and Sherman J.J. Evaluation of the relationship between depression and fibromyalgia syndrome: Why aren't all patients depressed?. J Rheumatol 27 (2000) 212-219
106. O'Malley P.G., Balden E., Tomkins G., Santoro J., Kroenke K., and Jackson J.L. Treatment of fibromyalgia with antidepressants. A meta-analysis. J Gen Intern Med 15 (2000) 659-666
107. Peters M., Schmidt A., Van den Hout M., Koopmans R., and Sluijter M. Chronic back pain, acute postoperative pain and activation of diffuse noxious inhibitory controls (DNIC). Pain 50 (1992) 177-187
108. Petzke F., Gracely R.H., Park K.M., Ambrose K., and Clauw D.J. What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol 30 (2003) 567-574
109. Quijada-Carrera J., Valenzuela A., Povedano-Gomez J., Fernandez-Rodriguez A., Hernanz-Mediano W., Gutierrez-Rubio A., de la Iglesia-Salgado J.L., and Garcia-Lopez A. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 65 (1996) 221-225
110. Raphael J.H., Southall J.L., Treharne G.J., and Kits G.D. Efficacy and adverse effects of lignocain therapy in fibromyalgia syndrome. BMC Musculoskel Disord 8 (2002) 21-26
111. Raspe H., and Baumgartner C. The epidemiology of the fibromyalgia syndrome (FMS): Different criteria - different results. J Musculoskel Pain 1 (1993) 149-152
112. Reilly P., and Littlejohn G. Peripheral arthralgic presentation of fibrositis/fibromyalgia syndrome. J Rheumatol 19 (1992) 281-283
113. Riedel W., Schlapp U., Leck S., Netter P., and Neeck G. Blunted ACTH and cortisol responses to systemic injection of corticotropine-releasing hormone (CRH) in fibromyalgia. Ann NY Acad Sci 966 (2002) 483-490
114. Rooks D., Silverman C., and Kantrowitz F. The effects of progressive strength training and aerobic exercise on muscle strength and cardiovascular fitness in women with fibromyalgia: a pilotstudy. Arthritis Rheum 47 (2002) 22-28
115. Rossy L., Buckelew S., Dorr N., Hagglund K., Thayer J., McIntosh M., Hewett J., and Johnson J. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 21 (1999) 180-191
116. Russell I. The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin N Am 28 (2002) 329-342
117. Russell I.J., Vaeroy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 5 (1992) 550-556
118. Salemi S., Rethage J., Wollina U., Michel B., Gay R., Gay S., and Sprott H. Detection of interleukin 1β (IL-1β), IL-6, and tumor necrosis factor-a in skin of patients with fibromyalgia. J Rheumatol 30 (2003) 146-150
119. Sarnoch H., Adler F., and Scholz O. Relevance of muscular sensitivity, muscular activity, and cognitive variables for pain reduction associated with EMG biofeedback in fibromyalgia. Percept Mot Skills 84 (1997) 1043-1050
120. Schochat T., and Raspe H. Elements of fibromyalgia in an open population. Rheumatol 42 (2003) 829-835
121. Scudds R.A., Rollman G.B., Harth M., and McCain G.A. Pain perception and personality measures as discriminators in the classification of fibrositis. J Rheumatol 14 (1987) 563-569
122. Siegel D., Janeway D., and Baum J. Fibromyalgia syndrome in children and adolescents: clinical features at presentation and status at follow-up. Pediatrics 101 (1998) 377-382
123. Simms R.W., Roy S.H., Hrovat M., Anderson J.J., Skrinar G., LePoole S.R., Zerbini C.A., Luca C.D., and Jolesz F. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum 37 (1994) 794-800
124. Sivri A., Cindas A., Dincer F., and Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Clin Rheumatol 15 (1996) 283-286
125. Smythe H.A. 'Fibrositis' as a disorder of pain modulation. Clin Rheum Dis 5 (1979) 823-832
126. Sorensen J., Graven-Nielsen T., Henriksson K.G., Bengtsson M., and Arendt-Nielsen L. Hyperexcitability in fibromyalgia. J Rheumatol 25 (1998) 152-155
127. Staud R., Vierck C.J., Cannon R.L., Mauderli A.P., and Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91 (2001) 165-175
128. Staud R., Cannon R., Mauderli A., Robinson M., Price D., and Vierck C. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain 102 (2003) 87-95
129. Stefano R.D., Selvi E., Villanova M., Frati E., Manganelli S., Franceschini E., Baisi G., and Marcolongo R. Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 27 (2000) 2906-2910
130. Svensson P., Arendt-Nielsen L., Nielsen H., and Larsen J.K. Effect of chronic and experimental jaw muscle pain on painpressure thresholds and stimulus-response curves. J Orofac Pain 9 (1995) 347-356
131. Tunks E., Cook J., Norman G., and Kalaher S. Tender points in fibromyalgia. Pain 34 (1988) 11-19
132. Turk D., Okifuji A., Sinclair J., and Starz T. Differential responses by psychosocial subgroups of fibromyalgia syndrome patients to an interdisciplinary treatment. Arthritis Care Res 11 (1998) 397-404
133. Vaeroy H., Qiao Z.-G., Morkrid L., and Forre O. Altered sympathetic nervous system response in patients with fibromyalgia (Fibrositis Syndrome). J Rheumatol 16 (1989) 1460-1465
134. Valim V., Oliveira L., Suda A., Silva L., Assis M., Neto T., Feldman D., and Natour J. Aerobic fitness effects in fibromyalgia. J Rheumatol 30 (2003) 1060-1069
135. VanDenderen J.C., Boersma J.W., Zeinstra P., Hollander A.P., and VanNeerbos B.R. Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): Is PFS a disorder of neuroendocrine reactivity?. Scand J Rheumatol 21 (1992) 35-37
136. VanHoudenhove B., Neerinckx E., Onghena P., Lysens R., and Vertommen H. Premorbid "overactive" lifestyle in chronic fatigue syndrome and fibromyalgia. An etiological factor or proof of good citizenship?. J Psychosom Res 51 (2001) 571-576
137. VanSanten M., Bolwijn P., Landewe R., Verstappen F., Bakker C., Hidding A., Kemp D.V.D., Houben H., and Linden S.V.D. High or low intensity aerobic fitness in fibromyalgia: does it matter?. J Rheumatol 29 (2002) 582-587
138. Vitton O., Gendreau M., Gendreau J., Kranzler J., and Rao S. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol Clin Exp 19 Suppl. 1 (2004) S27-S35
139. Wallace D., Linker-Israeli M., Hallegua D., Silverman S., Silver D., and Weisman M. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 40 (2001) 743-749
140. White K., Speechley M., Harth M., and Ostbye T. Comparing self-reported function and work disability in 100 community based cases of fibromyalgia syndrome versus controls in London, Ontario. Arthritis Rheum 42 (1999) 76-83
141. White K.P., Speechley M., Harth M., and Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26 (1999) 1570-1576
142. Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 56 (1997) 268-271
143. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Cambell S.M., Abeles M., Clark P., Gatter A.G., Hamaty D., Lessard J., Lichtbroun A.S., Masi A.T., McCain G.A., Reynolds W.J., Romano T.J., Russell I.J., and Sheon R.P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33 (1990) 160-172
144. Wolfe F., Simons D., Fricton J., Bennett R.M., Goldenberg D., Gerwin R., Hathaway D., McCain G., Russell I., Sanders H., and Skootsky S. The fibromyalgia and myofascial pain syndromes: A preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial painsyndrome and no disease. J Rheumatol 19 (1992) 944-951
145. Wolfe F., Ross K., Anderson J., Russell I.J., and Herbert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 (1995) 19-28